<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="EN">
  <front>
    <journal-meta><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="nlm-ta">PLoS Comput Biol</journal-id><journal-id journal-id-type="pmc">ploscomp</journal-id><!--===== Grouping journal title elements =====--><journal-title-group><journal-title>PLoS Computational Biology</journal-title></journal-title-group><issn pub-type="ppub">1553-734X</issn><issn pub-type="epub">1553-7358</issn><publisher>
        <publisher-name>Public Library of Science</publisher-name>
        <publisher-loc>San Francisco, USA</publisher-loc>
      </publisher></journal-meta>
    <article-meta><article-id pub-id-type="publisher-id">PCOMPBIOL-D-11-00277</article-id><article-id pub-id-type="doi">10.1371/journal.pcbi.1002144</article-id><article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Article</subject>
        </subj-group>
        <subj-group subj-group-type="Discipline-v2">
          <subject>Biology</subject>
          <subj-group>
            <subject>Computational biology</subject>
            <subj-group>
              <subject>Biochemical simulations</subject>
              <subject>Regulatory networks</subject>
            </subj-group>
          </subj-group>
          <subj-group>
            <subject>Immunology</subject>
            <subj-group>
              <subject>Antigen processing and recognition</subject>
              <subject>Major histocompatibility complex</subject>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline">
          <subject>Immunology</subject>
          <subject>Computational Biology</subject>
        </subj-group>
      </article-categories><title-group><article-title>A Peptide Filtering Relation Quantifies MHC Class I Peptide Optimization</article-title><alt-title alt-title-type="running-head">Quantifying MHC Class I Peptide Optimization</alt-title></title-group><contrib-group>
        <contrib contrib-type="author" equal-contrib="yes" xlink:type="simple">
          <name name-style="western">
            <surname>Dalchau</surname>
            <given-names>Neil</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1">
            <sup>*</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes" xlink:type="simple">
          <name name-style="western">
            <surname>Phillips</surname>
            <given-names>Andrew</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Goldstein</surname>
            <given-names>Leonard D.</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
          <xref ref-type="fn" rid="fn1">
            <sup>¤</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Howarth</surname>
            <given-names>Mark</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
          <xref ref-type="aff" rid="aff4">
            <sup>4</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Cardelli</surname>
            <given-names>Luca</given-names>
          </name>
          <xref ref-type="aff" rid="aff5">
            <sup>5</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Emmott</surname>
            <given-names>Stephen</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Elliott</surname>
            <given-names>Tim</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
          <xref ref-type="aff" rid="aff6">
            <sup>6</sup>
          </xref>
          <xref ref-type="fn" rid="fn1">
            <sup>¶</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Werner</surname>
            <given-names>Joern M.</given-names>
          </name>
          <xref ref-type="aff" rid="aff6">
            <sup>6</sup>
          </xref>
          <xref ref-type="aff" rid="aff7">
            <sup>7</sup>
          </xref>
          <xref ref-type="fn" rid="fn1">
            <sup>¶</sup>
          </xref>
        </contrib>
      </contrib-group><aff id="aff1"><label>1</label><addr-line>Biological Computation Group, Microsoft Research, Cambridge, United Kingdom</addr-line>       </aff><aff id="aff2"><label>2</label><addr-line>Department of Applied Mathematics and Theoretical Physics, University of Cambridge, Centre for Mathematical Sciences, Cambridge, United Kingdom</addr-line>       </aff><aff id="aff3"><label>3</label><addr-line>Faculty of Medicine, University of Southampton, Southampton, United Kingdom</addr-line>       </aff><aff id="aff4"><label>4</label><addr-line>Department of Biochemistry, Oxford University, Oxford, United Kingdom</addr-line>       </aff><aff id="aff5"><label>5</label><addr-line>Programming Principles and Tools Group, Microsoft Research, Cambridge, United Kingdom</addr-line>       </aff><aff id="aff6"><label>6</label><addr-line>Institute for Life Sciences, University of Southampton, Southampton, United Kingdom</addr-line>       </aff><aff id="aff7"><label>7</label><addr-line>School of Biological Sciences, Faculty of Natural Sciences and the Environment, University of Southampton, Southampton, United Kingdom</addr-line>       </aff><contrib-group>
        <contrib contrib-type="editor" xlink:type="simple">
          <name name-style="western">
            <surname>Chakraborty</surname>
            <given-names>Arup K.</given-names>
          </name>
          <role>Editor</role>
          <xref ref-type="aff" rid="edit1"/>
        </contrib>
      </contrib-group><aff id="edit1">Massachusetts Institute of Technology, United States of America</aff><author-notes>
        <corresp id="cor1">* E-mail: <email xlink:type="simple">ndalchau@microsoft.com</email></corresp>
        <fn fn-type="current-aff" id="fn1">
          <label>¤</label>
          <p>Current address: Wellcome Trust/Cancer Research UK Gurdon Institute, University of Cambridge, Cambridge, United Kingdom.</p>
        </fn>
        <fn fn-type="con">
          <p>Conceived and designed the experiments: ND AP MH LC TE JMW. Performed the experiments: ND AP LDG MH. Analyzed the data: ND MH. Contributed reagents/materials/analysis tools: AP. Wrote the paper: ND AP LDG MH LC SE TE JMW.</p>
        </fn>
        <fn fn-type="other" id="fn2">
          <p>¶ These authors are joint senior authors on this work.</p>
        </fn>
      <fn fn-type="conflict">
        <p>The authors have declared that no competing interests exist.</p>
      </fn></author-notes><pub-date pub-type="collection">
        <month>10</month>
        <year>2011</year>
      </pub-date><pub-date pub-type="epub">
        <day>13</day>
        <month>10</month>
        <year>2011</year>
      </pub-date><volume>7</volume><issue>10</issue><elocation-id>e1002144</elocation-id><history>
        <date date-type="received">
          <day>24</day>
          <month>2</month>
          <year>2011</year>
        </date>
        <date date-type="accepted">
          <day>18</day>
          <month>6</month>
          <year>2011</year>
        </date>
      </history><!--===== Grouping copyright info into permissions =====--><permissions><copyright-year>2011</copyright-year><copyright-holder>Dalchau et al</copyright-holder><license><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><abstract>
        <p>Major Histocompatibility Complex (MHC) class I molecules enable cytotoxic T lymphocytes to destroy virus-infected or cancerous cells, thereby preventing disease progression. MHC class I molecules provide a snapshot of the contents of a cell by binding to protein fragments arising from intracellular protein turnover and presenting these fragments at the cell surface. Competing fragments (peptides) are selected for cell-surface presentation on the basis of their ability to form a stable complex with MHC class I, by a process known as <italic>peptide optimization</italic>. A better understanding of the optimization process is important for our understanding of immunodominance, the predominance of some T lymphocyte specificities over others, which can determine the efficacy of an immune response, the danger of immune evasion, and the success of vaccination strategies. In this paper we present a dynamical systems model of peptide optimization by MHC class I. We incorporate the chaperone molecule tapasin, which has been shown to enhance peptide optimization to different extents for different MHC class I alleles. Using a combination of published and novel experimental data to parameterize the model, we arrive at a relation of <italic>peptide filtering</italic>, which quantifies peptide optimization as a function of peptide supply and peptide unbinding rates. From this relation, we find that tapasin enhances peptide unbinding to improve peptide optimization without significantly delaying the transit of MHC to the cell surface, and differences in peptide optimization across MHC class I alleles can be explained by allele-specific differences in peptide binding. Importantly, our filtering relation may be used to dynamically predict the cell surface abundance of any number of competing peptides by MHC class I alleles, providing a quantitative basis to investigate viral infection or disease at the cellular level. We exemplify this by simulating optimization of the distribution of peptides derived from Human Immunodeficiency Virus Gag-Pol polyprotein.</p>
      </abstract><abstract abstract-type="summary">
        <title>Author Summary</title>
        <p>Major Histocompatibility Complex (MHC) class I molecules bind to protein fragments (peptides) within the cell and present these fragments at the cell surface, thus providing a snapshot of the cell contents that can subsequently be used to trigger an immune response. Only a fraction of the potentially billions of peptides inside a cell are selected for presentation, and the process is optimized to select for peptides that form a stable complex with MHC class I. The mechanisms of the optimization process are important for predicting the efficacy of an immune response and for designing effective vaccines, yet are still not well-understood. In this article we present a dynamical systems model of peptide optimization by MHC class I. We show that peptide optimization can be quantified and mechanistically explained by a peptide filtering relation, which relates cell surface abundance to peptide supply, peptide unbinding and interactions with the chaperone molecule tapasin. The filtering relation also accounts for differences in optimization across MHC class I alleles. Finally, we show how the filtering relation can be used to quantify the cell-surface presentation of virus-derived peptides for immune system surveillance.</p>
      </abstract><funding-group><funding-statement>LDG was supported by an EPSRC studentship (UK). MH was funded by a Medical Research Council studentship (#G78/6999). TE was supported by a Cancer Research UK programme grant entitled "The Biochemistry of MHC Class I Assembly and its Immunological Consequences" (#C7056/A2739). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts>
        <page-count count="14"/>
      </counts></article-meta>
  </front>
  <body>
    <sec id="s1">
      <title>Introduction</title>
      <p>MHC class I molecules are encoded within the genetic region known as the Major Histocompatibility Complex and are present in all nucleated human cells. MHC class I molecules direct cytotoxic T lymphocytes (CTL) to destroy virus-infected or cancerous cells, thereby preventing disease progression <xref ref-type="bibr" rid="pcbi.1002144-Yewdell1">[1]</xref>. They provide a snapshot of the internal contents of a cell by binding to peptides arising from intracellular protein turnover and presenting these peptides at the cell surface, where the peptide-MHC complex can be recognized by CTL (<xref ref-type="fig" rid="pcbi-1002144-g001">Fig. 1</xref>). Most cells will present an array of tens of thousands of different peptides at their surface, some of which will be unique to virus-infected or cancerous cells. The efficacy of a CTL response to these peptides depends to a large extent on the ability of MHC class I molecules to select only a limited number of the potentially billions of different peptides that are generated by the hydrolysis of all intracellular proteins <xref ref-type="bibr" rid="pcbi.1002144-Yewdell2">[2]</xref>. Peptides are selected for presentation on the basis of their ability to form a stable complex with MHC class I, by a process known as <italic>peptide optimization</italic>. A better understanding of the optimization of peptides is important for our understanding of <italic>immunodominance</italic> <xref ref-type="bibr" rid="pcbi.1002144-Yewdell1">[1]</xref>, the predominance of some CTL specificities over others, which can determine the efficacy of an immune response, the danger of immune evasion, and the success of vaccination and immunotherapeutic strategies.</p>
      <fig id="pcbi-1002144-g001" position="float">
        <object-id pub-id-type="doi">10.1371/journal.pcbi.1002144.g001</object-id>
        <label>Figure 1</label>
        <caption>
          <title>Basic process of MHC class I antigen presentation.</title>
          <p>Degradation of cytosolic and nuclear proteins, predominantly by the proteasome, generates peptides that are actively transported into the lumen of the endoplasmic reticulum (ER). Loading and editing of peptide cargo on MHC class I is achieved in the peptide loading complex, resulting in loaded MHC class I being released into the Golgi and transported to the cell surface, where the MHC class I peptide complex is presented to the immune system via the T-cell receptor. Known constituents of the peptide loading complex such as the transporter for antigen processing (TAP), tapasin, ERp57, calreticulin and MHC heavy-chain together with <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e001" xlink:type="simple"/></inline-formula> are shown explicitly.</p>
        </caption>
        <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002144.g001" xlink:type="simple"/>
      </fig>
      <p>Peptide binding to MHC class I occurs in the endoplasmic reticulum (ER) and is assisted by multiple cofactors that are thought to enable the optimization process <xref ref-type="bibr" rid="pcbi.1002144-Elliott1">[3]</xref>. The transporter associated with antigen processing (TAP) supplies the lumen of the ER with peptides generated in the cytosol and forms the backbone of the peptide loading complex (PLC). A number of chaperone molecules also comprise the PLC, namely calreticulin, calnexin, ERp57 and importantly tapasin, which bridges the gap between MHC class I and TAP <xref ref-type="bibr" rid="pcbi.1002144-Wright1">[4]</xref> (<xref ref-type="fig" rid="pcbi-1002144-g001">Fig. 1</xref>). Of these chaperones, only tapasin is known to influence the extent of peptide optimization, in such a way as to skew the cell surface cargo towards peptides with low off-rates <xref ref-type="bibr" rid="pcbi.1002144-Howarth1">[5]</xref>, and this influence is known to vary across different MHC class I alleles <xref ref-type="bibr" rid="pcbi.1002144-Williams1">[6]</xref>.</p>
      <p>While a range of interactions between tapasin and MHC class I have previously been identified <xref ref-type="bibr" rid="pcbi.1002144-Praveen1">[7]</xref>, <xref ref-type="bibr" rid="pcbi.1002144-Chen1">[8]</xref>, the effects of these interactions on peptide optimization are still not well-understood. A recent study used computational modeling to distinguish between different hypotheses of tapasin function within the ER <xref ref-type="bibr" rid="pcbi.1002144-Schneeweiss1">[9]</xref>, but the model assumed that only peptides with low off-rates could egress to the cell-surface, and was therefore unable to predict the optimization of peptides with different off-rates. As a result, the model was unable to account for observed effects of tapasin on peptide optimization, both over time <xref ref-type="bibr" rid="pcbi.1002144-Williams1">[6]</xref> and at steady state <xref ref-type="bibr" rid="pcbi.1002144-Howarth1">[5]</xref>.</p>
      <p>In this paper we present a dynamical systems model for predicting MHC class I peptide optimization. We include interactions with the chaperone molecule tapasin, and propose a relation of <italic>peptide filtering</italic> to quantify peptide optimization as a function of peptide supply and peptide off-rates. Using a combination of published and novel experimental data, together with a combination of Bayesian inference and kinetic analysis, we show that tapasin can improve both the rate and extent of peptide optimization by accelerating peptide off-rate, and that differences in <italic>optimization</italic> across MHC class I alleles can be explained by an allele-specific peptide on-rate. Our filtering relation provides a mechanistic interpretation for recent experimental observations of peptide optimization both over time <xref ref-type="bibr" rid="pcbi.1002144-Williams1">[6]</xref> and at steady state <xref ref-type="bibr" rid="pcbi.1002144-Howarth1">[5]</xref>. Finally, we demonstrate how the filtering relation can be used to quantify optimization of a large set of competing peptides in the context of an immune response, by simulating the cell surface abundance of Human Immunodeficiency Virus (HIV) peptides in complex with different MHC class I alleles.</p>
    </sec>
    <sec id="s3">
      <title>Results</title>
      <sec id="s3a">
        <title>A model of MHC class I peptide optimization</title>
        <p>We formulated a dynamical systems model of MHC class I peptide optimization using a biological modeling language (SPiM <xref ref-type="bibr" rid="pcbi.1002144-Phillips1">[10]</xref>, Fig. S1 in <xref ref-type="supplementary-material" rid="pcbi.1002144.s003">Text S1</xref>) and exported the model to an equivalent set of biochemical reactions for further analysis (<xref ref-type="fig" rid="pcbi-1002144-g002">Fig. 2</xref>). The model characterizes the interactions between MHC, peptides and tapasin within the endoplasmic reticulum, together with the dynamics of egressed peptide-MHC complexes at the cell surface.</p>
        <fig id="pcbi-1002144-g002" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pcbi.1002144.g002</object-id>
          <label>Figure 2</label>
          <caption>
            <title>Indexed reactions for a dynamical systems model of MHC class I peptide optimization.</title>
            <p>Each shape in the model represents a molecular species and each box represents a reaction, where inbound edges represent reactants and outbound edges represent products. Boxes are labeled with corresponding reaction rates, where a single rate denotes an irreversible reaction and two rates denote a reversible reaction, with the rate of the forward reaction indicated on top. The subset of reactions taking place at the cell surface is given by <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e002" xlink:type="simple"/></inline-formula> (see <xref ref-type="sec" rid="s5">Methods</xref> for the full reaction set).</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002144.g002" xlink:type="simple"/>
        </fig>
        <p>A number of simplifying assumptions were made when constructing the model: (i) Peptides <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e003" xlink:type="simple"/></inline-formula> are supplied to the ER at rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e004" xlink:type="simple"/></inline-formula> and then degraded or removed from the ER at rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e005" xlink:type="simple"/></inline-formula>. Since different peptides <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e006" xlink:type="simple"/></inline-formula> can have different levels of abundance within the cytoplasm and different rates of TAP transport, each peptide is associated with its own generation rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e007" xlink:type="simple"/></inline-formula>. (ii) MHC class I heavy chain and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e008" xlink:type="simple"/></inline-formula>m are assumed to represent a single unit, where <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e009" xlink:type="simple"/></inline-formula>m dissociation from empty class I heavy chain is interpreted as a form of MHC degradation. (iii) All peptides are assumed to have a similar rate of binding <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e010" xlink:type="simple"/></inline-formula> to MHC, such that <italic>peptide affinity</italic> is determined by a peptide-specific rate of unbinding <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e011" xlink:type="simple"/></inline-formula>, and is defined as <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e012" xlink:type="simple"/></inline-formula>. This is motivated by the measurements in <xref ref-type="bibr" rid="pcbi.1002144-Gakamsky1">[11]</xref>. (iv) Since MHC, tapasin and peptide continually cycle between the ER and Golgi apparatus <xref ref-type="bibr" rid="pcbi.1002144-Paulsson1">[12]</xref>, <xref ref-type="bibr" rid="pcbi.1002144-Garstka1">[13]</xref>, we do not explicitly represent the Golgi as a separate compartment. Instead, we consider our ER compartment to include both the ER and Golgi, where the rate of egress <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e013" xlink:type="simple"/></inline-formula> represents the rate of transit from the Golgi to the cell surface. By representing this process as a first-order reaction, we are making the simplifying assumption that the quantity of peptide-MHC complexes which egress is related to the quantity of complexes in the ER. (v) MHC can load peptides in the presence of tapasin at a higher rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e014" xlink:type="simple"/></inline-formula>, which implicitly models the stabilization of TAP molecules by tapasin, but we neglect egress of tapasin-bound MHC, since tapasin retains MHC by bridging it to the TAP transporter <xref ref-type="bibr" rid="pcbi.1002144-Lehner1">[14]</xref>. (vi) Tapasin can increase the rate of peptide unbinding from MHC by a factor <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e015" xlink:type="simple"/></inline-formula> <xref ref-type="bibr" rid="pcbi.1002144-Chen1">[8]</xref>, while peptide can increase the rate of tapasin unbinding from MHC by a factor <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e016" xlink:type="simple"/></inline-formula> <xref ref-type="bibr" rid="pcbi.1002144-Wearsch1">[15]</xref>. Tapasin has been shown to increase the peptide off-rate to a similar extent for peptides with a range of off-rates, though some variation has been shown for certain classes of peptide <xref ref-type="bibr" rid="pcbi.1002144-Chen1">[8]</xref>. (vii) We neglect egress of empty MHC, which is retained and recycled in the ER by the chaperone calreticulin <xref ref-type="bibr" rid="pcbi.1002144-Gao1">[16]</xref>, <xref ref-type="bibr" rid="pcbi.1002144-Howe1">[17]</xref>. (viii) Furthermore, we assume that <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e017" xlink:type="simple"/></inline-formula>m dissociation from peptide-loaded or tapasin-bound class I heavy chain is negligible compared to <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e018" xlink:type="simple"/></inline-formula>m dissociation from empty class I heavy chain. (ix) Once at the cell-surface, peptide unbinds from MHC irreversibly at rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e019" xlink:type="simple"/></inline-formula>, and empty MHC is degraded at rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e020" xlink:type="simple"/></inline-formula>. These assumptions can be refined in future iterations of the model.</p>
      </sec>
      <sec id="s3b">
        <title>Predicting peptide optimization over time</title>
        <p>MHC class I HLA-B alleles were previously shown to differ in their ability to optimize their peptide cargo over time, both in the presence and absence of tapasin <xref ref-type="bibr" rid="pcbi.1002144-Williams1">[6]</xref>. Specifically, the HLA-B4402 (B4402) allele was shown to be highly dependent on tapasin for peptide optimization, while the HLA-B2705 (B2705) and HLA-B4405 (B4405) alleles were shown to be less tapasin-dependent. B2705 is of particular interest because it is a susceptibility factor for certain autoimmune diseases and is associated with long-term non-progression of HIV <xref ref-type="bibr" rid="pcbi.1002144-Goulder1">[18]</xref>. Therefore, we sought to use our peptide optimization model to explain the variation in tapasin-dependence between HLA-B alleles, through a combination of model simulation and Information Theory.</p>
        <p>We simulated pulse-chase experiments <xref ref-type="bibr" rid="pcbi.1002144-Williams1">[6]</xref> using the peptide optimization model of <xref ref-type="fig" rid="pcbi-1002144-g002">Fig. 2</xref> , with representative peptides of low, medium and high affinity (<xref ref-type="supplementary-material" rid="pcbi.1002144.s003">Text S1</xref>). The experiments followed the thermostability of fixed cohorts of MHC class I complexes over time, making use of the known correlation between the thermostability of complexes and the affinity of their peptide cargo. Specifically, complexes stable at <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e021" xlink:type="simple"/></inline-formula> were shown to contain only high affinity peptides, complexes stable at <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e022" xlink:type="simple"/></inline-formula> were shown to contain a combination of medium and high affinity peptides, while all complexes were shown to be stable at <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e023" xlink:type="simple"/></inline-formula>, including empty MHC. Since the measurements correspond to both ER-localized and egressed peptide-MHC complexes, our assessment of the model was performed by comparing total peptide-MHC complexes with the <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e024" xlink:type="simple"/></inline-formula> measurement, total medium and high affinity complexes with the <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e025" xlink:type="simple"/></inline-formula> measurements, and total high affinity complexes with the <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e026" xlink:type="simple"/></inline-formula> measurements. Since many of the kinetic parameters of the model have not previously been measured directly, due to the technical difficulties involved in obtaining such measurements, we used heuristic search methods to infer the parameter values from the experimental data <xref ref-type="bibr" rid="pcbi.1002144-Williams1">[6]</xref> (see <xref ref-type="sec" rid="s5">Methods</xref>). Essentially, this involved finding values for the parameters which minimized the deviation between the experimental data and the corresponding model simulation. Using this approach, we investigated how allelic variation in HLA-B might affect peptide optimization, by distinguishing between <italic>allele parameters</italic>, which were allowed to vary between alleles, and <italic>fixed parameters</italic>, which were assumed to be invariant between alleles. Each hypothesized set of allele parameters defined a variant of the model, which possessed a different intrinsic ability to reproduce the observed dynamics.</p>
        <p>The Bayesian Information Criterion (BIC) <xref ref-type="bibr" rid="pcbi.1002144-Konishi1">[19]</xref> was used to quantify the performance of each set of allele parameters (equation (18) in <xref ref-type="sec" rid="s5">Methods</xref>). BIC incorporates a term which penalizes the deviation of the simulation from the data, and a second term which penalizes increasing numbers of allele parameters. Therefore, BIC can be used to assess a range of models by taking into account the added cost of additional unconstrained variables. Since the dynamics of peptide optimization varied considerably between HLA–B alleles in the absence of tapasin <xref ref-type="bibr" rid="pcbi.1002144-Williams1">[6]</xref>, we reasoned that at least one allele parameter must be tapasin-independent. To incorporate this insight whilst focusing on the principal contributors to allelic variation, we examined combinations of up to two allele parameters, with at least one tapasin-independent parameter selected from <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e027" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e028" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e029" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e030" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e031" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e032" xlink:type="simple"/></inline-formula>.The best BIC scores were obtained when the peptide on-rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e033" xlink:type="simple"/></inline-formula> was the only allele parameter (470.38), and when both <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e034" xlink:type="simple"/></inline-formula> and the rate of egress <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e035" xlink:type="simple"/></inline-formula> were the allele parameters (469.39; <xref ref-type="fig" rid="pcbi-1002144-g003">Fig. 3</xref>), suggesting that at least peptide on-rate is allele-specific. However, having both <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e036" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e037" xlink:type="simple"/></inline-formula> as allele parameters required unrealistically fast egress of B2705 and B4405 complexes to obtain a closer fit to the data (Fig. S2 in <xref ref-type="supplementary-material" rid="pcbi.1002144.s003">Text S1</xref>). Therefore a single allele parameter (<xref ref-type="fig" rid="pcbi-1002144-g004">Fig. 4</xref>) <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e038" xlink:type="simple"/></inline-formula> was used, which was able to effectively account for the experimental data <xref ref-type="bibr" rid="pcbi.1002144-Williams1">[6]</xref>. Specifically, in the absence of tapasin B4402 exhibited worse time-dependent optimization than both B2705 and B4405 (<xref ref-type="fig" rid="pcbi-1002144-g004">Fig. 4 A</xref>), while in the presence of tapasin B4402 exhibited better time-dependent optimization than both of these alleles (<xref ref-type="fig" rid="pcbi-1002144-g004">Fig. 4 B</xref>). To ensure that the MCMC search algorithm was robust to random variations, and could reproducibly generate consistent parameter estimates, we produced 10 different chains for each model hypothesis. For the allele-specific <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e039" xlink:type="simple"/></inline-formula> model, 8 out of 10 chains converged to BIC values between 470.38 and 470.69, while the other two chains performed poorly. We next plotted the mean and standard deviation of the posterior distributions of the model parameters for each of the 10 chains, which revealed that the 8 high performing chains had overlapping posterior distributions (Fig. S3 in <xref ref-type="supplementary-material" rid="pcbi.1002144.s003">Text S1</xref>), and were therefore producing consistent parameter estimates.</p>
        <fig id="pcbi-1002144-g003" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pcbi.1002144.g003</object-id>
          <label>Figure 3</label>
          <caption>
            <title>Selection of HLA–B allele parameters.</title>
            <p>The horizontal axis indicates the set of parameters that were allowed to vary between alleles. The vertical axis quantifies the Bayesian information criterion (BIC) of the best parameter values for a given set of allele parameters. BIC penalizes deviations of the model simulation from the experimental data, whilst also penalizing models with more variable parameters, implying that low BIC values correspond to more representative models. The best parameter values for a given set of allele parameters were inferred using the Filzbach MCMC software (see <xref ref-type="sec" rid="s5">Methods</xref>).</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002144.g003" xlink:type="simple"/>
        </fig>
        <fig id="pcbi-1002144-g004" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pcbi.1002144.g004</object-id>
          <label>Figure 4</label>
          <caption>
            <title>Simulation of time-dependent peptide optimization by HLA–B.</title>
            <p>The peptide optimization model of <xref ref-type="fig" rid="pcbi-1002144-g002">Fig. 2</xref> was used to simulate a labeled cohort of peptide-MHC complexes by switching from generation of an unlabeled MHC population to a labeled population for 5 min (yellow blocks). The plots represent the concentration of total labeled MHC (blue), labeled MHC with medium or high affinity peptide (green) and labeled MHC with high affinity peptide only (red), at each time point. Simulations were performed in the absence (<bold>A</bold>) and presence (<bold>B</bold>) of tapasin. Corresponding experimental results <xref ref-type="bibr" rid="pcbi.1002144-Williams1">[6]</xref> are also reported (circles). Simulations were conducted for representative low, medium and high affinity peptides with a separate dissociation rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e040" xlink:type="simple"/></inline-formula> and generation rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e041" xlink:type="simple"/></inline-formula> for each peptide <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e042" xlink:type="simple"/></inline-formula>, and a separate peptide binding rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e043" xlink:type="simple"/></inline-formula> for each HLA–B allele <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e044" xlink:type="simple"/></inline-formula> (Table S1 in <xref ref-type="supplementary-material" rid="pcbi.1002144.s003">Text S1</xref>; <xref ref-type="supplementary-material" rid="pcbi.1002144.s001">Protocol S1</xref>).</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002144.g004" xlink:type="simple"/>
        </fig>
        <p>To understand the effects of an allele-specific peptide on-rate on peptide optimization, we plotted MHC complexes with high, medium, and low affinity peptide separately, and distinguished free and tapasin-bound MHC complexes within the ER and at the cell surface (Fig. S4 in <xref ref-type="supplementary-material" rid="pcbi.1002144.s003">Text S1</xref>). For B4402 without tapasin, an intrinsically low peptide on-rate meant that the majority of B4402 complexes remained in the ER without peptide, resulting in very low optimization. For B2705 and B4405 without tapasin, an intrinsically high peptide on-rate meant that these alleles rapidly bound their peptide cargo and exhibited good time-dependent optimization. In contrast, for B4402 with tapasin, most complexes first bound to tapasin and were subsequently able to rapidly bind peptides and optimize their peptide cargo, presenting almost exclusively high affinity peptides at the cell surface. For B2705 and B4405 with tapasin, the intrinsically high peptide on-rate meant that peptide out-competed tapasin for binding to MHC, such that a higher proportion of peptides followed the non-tapasin pathway, resulting in reduced optimization. Thus, variation in the intrinsic ability of free HLA–B alleles to bind peptide in the absence of tapasin was shown to be the most likely explanation for allelic variation in peptide optimization, both in the presence and absence of tapasin. For all three alleles, cell surface optimization could not be improved by modifying most other parameters in the model (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e045" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e046" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e047" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e048" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e049" xlink:type="simple"/></inline-formula>) (Fig. S5 in <xref ref-type="supplementary-material" rid="pcbi.1002144.s003">Text S1</xref>). This indicates that the balance between peptide binding <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e050" xlink:type="simple"/></inline-formula> and tapasin binding <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e051" xlink:type="simple"/></inline-formula> is a major determinant of peptide optimization, achieved by controlling the effectiveness of the tapasin-mediated pathway. The prediction that allele-specific tapasin dependency results from variations in peptide binding to MHC class I molecules is consistent with analysis from molecular dynamics simulations, which suggest that tapasin stabilizes peptide-receptive conformations <xref ref-type="bibr" rid="pcbi.1002144-Sieker1">[20]</xref>. This stabilization in the presence of tapasin is represented in our model by setting the binding rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e052" xlink:type="simple"/></inline-formula> to be allele-independent and greater than or equal to the binding rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e053" xlink:type="simple"/></inline-formula>. In the absence of tapasin, MHC class I molecules of different alleles may have varying levels of peptide receptiveness, which is represented in our model by allowing <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e054" xlink:type="simple"/></inline-formula> to vary between alleles.</p>
      </sec>
      <sec id="s3c">
        <title>Kinetic control of peptide optimization</title>
        <p>Having established a hypothesis which explains how MHC alleles experience differential tapasin-dependence, we sought to identify the mechanisms that determine the extent and rate of peptide optimization, both in the presence and absence of tapasin. Peptide optimization is the process by which high affinity peptides are selected for presentation at the cell surface <xref ref-type="bibr" rid="pcbi.1002144-Williams1">[6]</xref>. Peptide-MHC complexes generally need to be stable for many hours or days at the cell surface in order to effectively elicit an immune response <xref ref-type="bibr" rid="pcbi.1002144-vanderBurg1">[21]</xref>, yet peptide optimization in the ER is typically limited to tens of minutes <xref ref-type="bibr" rid="pcbi.1002144-Elliott1">[3]</xref>, <xref ref-type="bibr" rid="pcbi.1002144-Williams1">[6]</xref>, <xref ref-type="bibr" rid="pcbi.1002144-Lewis1">[22]</xref>. This requires optimization beyond the limit that would be obtained in equilibrium. How such high optimization is achieved in so little time is still not well-understood <xref ref-type="bibr" rid="pcbi.1002144-Elliott1">[3]</xref>.</p>
        <p>One way to increase the extent of peptide optimization is for peptide-MHC complexes to be retained in the ER for an extended period prior to egress, so that unstable peptides have an opportunity to unbind <xref ref-type="bibr" rid="pcbi.1002144-Lewis1">[22]</xref>. However, delaying egress also increases the time for complexes to reach the cell surface. Therefore, a trade-off exists between the extent of optimization and the rate at which this optimization can be achieved. We quantify this trade-off by calculating the relative probabilities of MHC egress and peptide unbinding.</p>
        <p>Consider an MHC complex containing a peptide with off-rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e055" xlink:type="simple"/></inline-formula> (<xref ref-type="fig" rid="pcbi-1002144-g005">Fig. 5 A</xref>). The complex can either egress to the cell surface at rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e056" xlink:type="simple"/></inline-formula>, or the peptide can unbind at rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e057" xlink:type="simple"/></inline-formula>. The probability of each event is proportional to its rate, such that the probability of egress is given by <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e058" xlink:type="simple"/></inline-formula>. The competition between unbinding <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e059" xlink:type="simple"/></inline-formula> and egress <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e060" xlink:type="simple"/></inline-formula> defines a <italic>peptide filtering</italic> step, where the basic filtering mechanism is comparable to principles of kinetic proof-reading <xref ref-type="bibr" rid="pcbi.1002144-Hopfield1">[23]</xref>. Let <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e061" xlink:type="simple"/></inline-formula> denote the expected number of peptide-MHC complexes that egress to the cell surface before the peptide can escape (<xref ref-type="fig" rid="pcbi-1002144-g005">Fig. 5 A</xref>). If there are <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e062" xlink:type="simple"/></inline-formula> MHC complexes containing peptides with off-rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e063" xlink:type="simple"/></inline-formula> in the ER, we expect <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e064" xlink:type="simple"/></inline-formula> to egress and the remainder to release their peptide cargo. For very high <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e065" xlink:type="simple"/></inline-formula>, all <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e066" xlink:type="simple"/></inline-formula> complexes will egress irrespective of their peptide cargo. For very low <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e067" xlink:type="simple"/></inline-formula>, the number of egressed complexes will tend to <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e068" xlink:type="simple"/></inline-formula>. Let <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e069" xlink:type="simple"/></inline-formula> denote the proportion of egressed MHC complexes containing peptides with off-rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e070" xlink:type="simple"/></inline-formula> (<xref ref-type="fig" rid="pcbi-1002144-g005">Fig. 5 A</xref>). This defines a measure of <italic>peptide optimization</italic>. For very high egress we observe no optimization, where the proportion of peptides at the cell surface is equal to the proportion of peptides in the ER. For very low egress we observe maximum optimization, where the proportion of peptides at the cell surface varies inversely with the peptide off-rate.</p>
        <fig id="pcbi-1002144-g005" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pcbi.1002144.g005</object-id>
          <label>Figure 5</label>
          <caption>
            <title>Filtering relation of MHC class I peptide optimization.</title>
            <p>(<bold>A</bold>) Consider a population of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e071" xlink:type="simple"/></inline-formula> MHC complexes containing peptides with off-rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e072" xlink:type="simple"/></inline-formula>. <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e073" xlink:type="simple"/></inline-formula> denotes the expected number of MHC complexes that will egress before the peptide can escape. <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e074" xlink:type="simple"/></inline-formula> denotes the expected proportion of egressed MHC complexes that will contain peptides with off-rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e075" xlink:type="simple"/></inline-formula>. This defines a measure of peptide optimization. We plot <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e076" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e077" xlink:type="simple"/></inline-formula> as functions of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e078" xlink:type="simple"/></inline-formula> for three peptides with different off-rates and the same initial populations. Maximal optimization is achieved when <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e079" xlink:type="simple"/></inline-formula>, with <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e080" xlink:type="simple"/></inline-formula> (dashed lines). (<bold>B</bold>) Consider a population of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e081" xlink:type="simple"/></inline-formula> tapasin-MHC complexes containing peptides with off-rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e082" xlink:type="simple"/></inline-formula>. <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e083" xlink:type="simple"/></inline-formula> denotes the expected number of MHC complexes that will unbind from tapasin <italic>and</italic> egress before the peptide can escape, where <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e084" xlink:type="simple"/></inline-formula>. <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e085" xlink:type="simple"/></inline-formula> is defined as in A. We plot <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e086" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e087" xlink:type="simple"/></inline-formula> as functions of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e088" xlink:type="simple"/></inline-formula> with <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e089" xlink:type="simple"/></inline-formula> (black line in A). Maximal optimization is achieved when <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e090" xlink:type="simple"/></inline-formula>, with <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e091" xlink:type="simple"/></inline-formula>.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002144.g005" xlink:type="simple"/>
        </fig>
        <p>The introduction of tapasin provides an additional filtering step (<xref ref-type="fig" rid="pcbi-1002144-g005">Fig. 5 B</xref>), involving a competition between peptide unbinding <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e092" xlink:type="simple"/></inline-formula> and tapasin unbinding <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e093" xlink:type="simple"/></inline-formula>. Let <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e094" xlink:type="simple"/></inline-formula> denote the expected number of MHC complexes that unbind from tapasin <italic>and</italic> egress to the cell surface before the peptide can escape (<xref ref-type="fig" rid="pcbi-1002144-g005">Fig. 5 B</xref>). For very high <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e095" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e096" xlink:type="simple"/></inline-formula>, all <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e097" xlink:type="simple"/></inline-formula> complexes will egress irrespective of their peptide cargo. For very low <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e098" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e099" xlink:type="simple"/></inline-formula>, the number of egressed peptide-MHC complexes will tend to <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e100" xlink:type="simple"/></inline-formula>. The number of egressed complexes therefore varies with <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e101" xlink:type="simple"/></inline-formula> in the presence of tapasin (<xref ref-type="fig" rid="pcbi-1002144-g005">Fig. 5 B</xref>), compared with <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e102" xlink:type="simple"/></inline-formula> in the absence of tapasin (<xref ref-type="fig" rid="pcbi-1002144-g005">Fig. 5 A</xref>). This implies that tapasin enhances presentation according to peptide affinity <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e103" xlink:type="simple"/></inline-formula>, in agreement with experimental results <xref ref-type="bibr" rid="pcbi.1002144-Howarth1">[5]</xref>. Since the proportion of egressed complexes now varies inversely with the <italic>square</italic> of peptide off-rate, low affinity peptides are much more likely to escape than high affinity peptides, resulting in improved peptide optimization.</p>
        <p>The peptide filtering relation presented above also holds for the full dynamical systems model of <xref ref-type="fig" rid="pcbi-1002144-g002">Fig. 2</xref> , in which peptides can bind and unbind multiple times to MHC. By translating the reactions of <xref ref-type="fig" rid="pcbi-1002144-g002">Fig. 2</xref> to a set of ordinary differential equations, we obtained the following expression for the steady-state concentration of peptide-MHC complexes at the cell surface (see <xref ref-type="sec" rid="s5">Methods</xref>):<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e104" xlink:type="simple"/><label>(1)</label></disp-formula></p>
        <p>where <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e105" xlink:type="simple"/></inline-formula>. The equation includes the ER peptide filtering steps described in <xref ref-type="fig" rid="pcbi-1002144-g005">Fig. 5</xref>, together with peptide optimization at the cell surface given by <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e106" xlink:type="simple"/></inline-formula>, where peptides with a lower off-rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e107" xlink:type="simple"/></inline-formula> are more likely to remain bound to MHC. The equation also quantifies the ratio of egressed peptide-MHC complexes that are loaded in the presence and absence of tapasin, given by the ratio of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e108" xlink:type="simple"/></inline-formula> to <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e109" xlink:type="simple"/></inline-formula>. Assuming peptide loading takes place via the tapasin pathway (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e110" xlink:type="simple"/></inline-formula>) and that peptides have a high turnover in the ER <xref ref-type="bibr" rid="pcbi.1002144-Blanchard1">[24]</xref>, characterized by high generation and degradation rates (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e111" xlink:type="simple"/></inline-formula>), we can simplify equation (1) as<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e112" xlink:type="simple"/><label>(2)</label></disp-formula></p>
        <p>where <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e113" xlink:type="simple"/></inline-formula>. This corresponds to an upper bound on peptide optimization in the presence of tapasin. In the absence of tapasin, the equation for <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e114" xlink:type="simple"/></inline-formula> is the same as (2) but without the tapasin optimization step <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e115" xlink:type="simple"/></inline-formula>. This implies that tapasin enhances peptide presentation according to peptide affinity <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e116" xlink:type="simple"/></inline-formula>, in agreement with the analysis of <xref ref-type="fig" rid="pcbi-1002144-g005">Fig. 5</xref> and experimental findings <xref ref-type="bibr" rid="pcbi.1002144-Howarth1">[5]</xref>.</p>
        <p>To further place our insights in a biological context, we used the dynamical systems model to identify the mechanisms that determine the rate of peptide optimization. Consider the filtering step between peptide unbinding <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e117" xlink:type="simple"/></inline-formula> and tapasin unbinding <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e118" xlink:type="simple"/></inline-formula>. Tapasin can enhance peptide optimization to the same extent either by increasing the peptide off-rate by a given factor <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e119" xlink:type="simple"/></inline-formula>, or by decreasing the tapasin unbinding rate by the same factor. However, decreasing the tapasin unbinding rate essentially delays the transit of MHC to the cell surface, resulting in slower optimization. In contrast, increasing the peptide off-rate allows tapasin to increase the extent of peptide optimization while still maintaining a rapid flux of peptide-MHC complexes to the cell surface.</p>
      </sec>
      <sec id="s3d">
        <title>Predicting peptide optimization at steady-state</title>
        <p>To further probe the applicability of our model, we investigated whether it could be used to predict peptide optimization at steady state. Previously, the effects of tapasin on steady-state peptide optimization were measured for peptides in the MHC class I allele H2−<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e120" xlink:type="simple"/></inline-formula> (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e121" xlink:type="simple"/></inline-formula>) <xref ref-type="bibr" rid="pcbi.1002144-Howarth1">[5]</xref>. The experiments were conducted using four target peptides, obtained by performing substitutions at positions 5 and 8 of the amino acid sequence SIINFEKL. Peptide off-rates were measured in RMA-S cells and each of the target peptides were introduced as minigenes into a tapasin-deficient cell line (.220) and into the same cell line transfected with tapasin (.220.Tpn). Steady-state levels of cell surface peptide-MHC complexes were measured by flow cytometry using mAb 25.D1 (<xref ref-type="fig" rid="pcbi-1002144-g006">Fig. 6 C</xref>, Table S3 in <xref ref-type="supplementary-material" rid="pcbi.1002144.s003">Text S1</xref>), which specifically recognizes the SIINFEKL peptide variants bound to <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e122" xlink:type="simple"/></inline-formula> <xref ref-type="bibr" rid="pcbi.1002144-Porgador1">[25]</xref>. Total cell-surface MHC was also measured with mAb Y3, which recognizes empty and peptide-occupied <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e123" xlink:type="simple"/></inline-formula> (<xref ref-type="fig" rid="pcbi-1002144-g006">Fig. 6 D</xref>, Table S3 in <xref ref-type="supplementary-material" rid="pcbi.1002144.s003">Text S1</xref>).</p>
        <fig id="pcbi-1002144-g006" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pcbi.1002144.g006</object-id>
          <label>Figure 6</label>
          <caption>
            <title>Peptide optimization and trafficking for H2−K.</title>
            <p><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e124" xlink:type="simple"/></inline-formula> The model of <xref ref-type="fig" rid="pcbi-1002144-g002">Fig. 2</xref> was calibrated for H2−<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e125" xlink:type="simple"/></inline-formula> by varying the rates of peptide binding, MHC degradation at the cell surface, and egress (Table S2 in <xref ref-type="supplementary-material" rid="pcbi.1002144.s003">Text S1</xref>; <xref ref-type="supplementary-material" rid="pcbi.1002144.s002">Protocol S2</xref>). Each simulation computes the steady state of the model with three types of peptide: two background peptides <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e126" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e127" xlink:type="simple"/></inline-formula> and one of the four SIINFEKL peptide variants <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e128" xlink:type="simple"/></inline-formula> (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e129" xlink:type="simple"/></inline-formula> estimated from data in panel A). (<bold>A</bold>) Release of peptides from MHC following treatment with brefeldin A (BFA) measured with 25.D1 (symbols), fitted to single exponential decays (solid lines). (<bold>B</bold>) Dissociation of endogenous peptides from cells treated with BFA. (<bold>C</bold>) Steady-state presentation of specific peptide-MHC complexes at the cell surface, comparing simulation with measurements of 25.D1 from <xref ref-type="bibr" rid="pcbi.1002144-Howarth1">[5]</xref>. (<bold>D</bold>) Total steady-state peptide-MHC complexes (cell surface), comparing simulation with measurements of Y3 from <xref ref-type="bibr" rid="pcbi.1002144-Howarth1">[5]</xref>. Simulated values were scaled by a proportionality factor for optimally overlapping the 25.D1 data (with SIINFEKM removed) and the Y3 data (all points) (<xref ref-type="supplementary-material" rid="pcbi.1002144.s003">Text S1</xref>). (B–D) The x-axis shows the relative affinity of peptides given by the inverse of the off-rate. Steady state concentrations were obtained by equating the right hand sides of the ODEs to zero. Steady state concentrations in tapasin-deficient cells were simulated by setting <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e130" xlink:type="simple"/></inline-formula>. (<bold>E–G</bold>) For quantifying egression of peptide-MHC complexes, .220.<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e131" xlink:type="simple"/></inline-formula> (E) and .220.<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e132" xlink:type="simple"/></inline-formula>.Tpn (F) were pulsed for 10 min with <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e133" xlink:type="simple"/></inline-formula>-Met/Cys and chased for the indicated times (min). Y3 immunoprecipitates were digested with endoglycosidase-H (EndoH) and SDS-PAGE and autoradiography were performed. Arrows indicate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e134" xlink:type="simple"/></inline-formula> heavy chain resistant (R) and sensitive (S) to EndoH digestion. EndoH analysis of H2−<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e135" xlink:type="simple"/></inline-formula> was performed as described previously <xref ref-type="bibr" rid="pcbi.1002144-Williams1">[6]</xref>. (B–D, G) The solid lines indicate model simulations and triangles indicate measured data-points. The experimental data for (A,B,E–F) is novel, while the experimental data for (C,D) is from <xref ref-type="bibr" rid="pcbi.1002144-Howarth1">[5]</xref>.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002144.g006" xlink:type="simple"/>
        </fig>
        <p>We complemented previous experimentation <xref ref-type="bibr" rid="pcbi.1002144-Howarth1">[5]</xref> by measuring the off-rates of the target peptides in .220 cells directly. Cells were treated with Brefeldin A (BFA) to prevent further MHC egress, allowing direct characterization of the dissociation of cell-surface MHC complexes carrying SIINFEKL peptide variants with 25.D1. The off-rates of the target peptides were estimated by fitting single exponential decays (SIINFEKL: <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e136" xlink:type="simple"/></inline-formula>, SIINFEKV: <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e137" xlink:type="simple"/></inline-formula>, SIINFEKM: <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e138" xlink:type="simple"/></inline-formula>, SIINYEKL: <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e139" xlink:type="simple"/></inline-formula>; <xref ref-type="fig" rid="pcbi-1002144-g006">Fig. 6 A</xref>). We also used Y3 to measure total MHC during BFA incubation of cells with no target peptide, in the presence and absence of tapasin, to provide an indication of the off-rates of endogenous peptides presented by .220 and .220.Tpn cells (<xref ref-type="fig" rid="pcbi-1002144-g006">Fig. 6 B</xref>).</p>
        <p>We simulated the above experiments using the peptide optimization model of <xref ref-type="fig" rid="pcbi-1002144-g002">Fig. 2</xref> with a parameter set specific to H2−<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e140" xlink:type="simple"/></inline-formula> (Table S2 and Fig. S6 in <xref ref-type="supplementary-material" rid="pcbi.1002144.s003">Text S1</xref>). The full range of endogenous peptides was characterized by two representative peptides with off-rates <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e141" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e142" xlink:type="simple"/></inline-formula>, and supply rates <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e143" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e144" xlink:type="simple"/></inline-formula> (<xref ref-type="supplementary-material" rid="pcbi.1002144.s003">Text S1</xref>). Each experiment was simulated using one of the target peptides with off-rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e145" xlink:type="simple"/></inline-formula>, together with the representative endogenous peptides. Since target peptides were expressed at approximately equal levels inside cells <xref ref-type="bibr" rid="pcbi.1002144-Howarth1">[5]</xref>, we assumed that they were generated at the same rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e146" xlink:type="simple"/></inline-formula>. The model simulations agreed with the trends observed experimentally, accurately recapitulating the enhancement of steady state optimization conferred by tapasin (<xref ref-type="fig" rid="pcbi-1002144-g006">Fig. 6</xref> C, D, Table S3 in <xref ref-type="supplementary-material" rid="pcbi.1002144.s003">Text S1</xref>). However, we observed that the model did not fit the experimental data for SIINFEKM as well as for the other target peptides. We hypothesized that the poor fit could be caused by increased TAP transport of the SIINFEKM peptide, due to a change in the terminal residue at position 8 <xref ref-type="bibr" rid="pcbi.1002144-Peters1">[26]</xref>. To explore this idea, we increased the generation rate of SIINFEKM by a factor of 2.5, which gave a better fit to the experimental results (<xref ref-type="fig" rid="pcbi-1002144-g006">Fig. 6 D</xref>). This hypothesis further highlights the potential importance of peptide supply in predicting relative presentation levels <xref ref-type="bibr" rid="pcbi.1002144-Tenzer1">[27]</xref>, as can be seen from the peptide filtering relation (2). Although experimental measurements were only obtained for four distinct peptides, the model predicts the presentation levels for a continuum of peptide off-rates over a broad range, which can be checked in future experiments.</p>
        <p>To distinguish between optimization resulting from delayed tapasin unbinding versus enhanced peptide off-rate, we measured the time taken for a fixed cohort of pulse-labeled MHC complexes to reach the cell surface by measuring endoglycosidase-H (EndoH) resistance (<xref ref-type="fig" rid="pcbi-1002144-g006">Fig. 6 E–G</xref>). By taking into account the temporal constraints of the EndoH data, we found that enhanced peptide off-rates were required to allow increased peptide optimization in the presence of tapasin without significantly delaying the transit of peptide-MHC complexes to the cell surface (see Fig. S7 in <xref ref-type="supplementary-material" rid="pcbi.1002144.s003">Text S1</xref>). Further parameter variation analysis indicated that cell surface optimization is nearly maximal in the H2−<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e147" xlink:type="simple"/></inline-formula> model with respect to <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e148" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e149" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e150" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e151" xlink:type="simple"/></inline-formula>, but could be improved by reducing <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e152" xlink:type="simple"/></inline-formula> (Fig. S8 in <xref ref-type="supplementary-material" rid="pcbi.1002144.s003">Text S1</xref>). However, reducing <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e153" xlink:type="simple"/></inline-formula> decreases the export of peptide-MHC complexes, suggesting a possible trade-off between optimization and the efflux of new information concerning cellular protein content.</p>
      </sec>
      <sec id="s3e">
        <title>Predicting optimization of viral peptides</title>
        <p>To illustrate how the peptide optimization model may be used in more realistic scenarios, we simulated the presentation of HIV-derived peptides using our models for the HIV-associated allele HLA–B2705 (B2705), and HLA–B4402 (B4402) for comparison. Peptides between 8 and 10 amino acids in length were identified from the Gag-Pol polyprotein (UniProt; accession P03367) and assessed for their off-rates using the BIMAS prediction algorithm <xref ref-type="bibr" rid="pcbi.1002144-Parker1">[28]</xref>. For B2705, the slowest off-rate identified was for the immunodominant KRWIILGLNK (positions 262–272) epitope <xref ref-type="bibr" rid="pcbi.1002144-Nixon1">[29]</xref> (off-rate: <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e154" xlink:type="simple"/></inline-formula>). For B4402, the allele parameters of the BIMAS algorithm were not available, so we quantified off-rates based on the BIMAS algorithm parameters for the closely related allele B4403. The off-rates identified were generally higher than for B2705 (<xref ref-type="fig" rid="pcbi-1002144-g007">Fig. 7 A</xref>). When comparing simulations of B4402 in the presence and absence of tapasin, the highest affinity peptide AETGQETAY (positions 1250–1258; off-rate: <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e155" xlink:type="simple"/></inline-formula>) was enhanced by a factor of 445 by tapasin (<xref ref-type="fig" rid="pcbi-1002144-g007">Fig. 7 B</xref>), though cell surface presentation was over 25 times less than the presentation of KRWIILGLNK by B2705 (<xref ref-type="fig" rid="pcbi-1002144-g007">Fig. 7 B</xref>). Despite B2705 being a relatively tapasin-independent allele <xref ref-type="bibr" rid="pcbi.1002144-Williams1">[6]</xref> (<xref ref-type="fig" rid="pcbi-1002144-g004">Fig. 4</xref>), tapasin significantly enhanced presentation of peptide KRWIILGLNK by a factor of 120 (<xref ref-type="fig" rid="pcbi-1002144-g007">Fig. 7 C</xref>).</p>
        <fig id="pcbi-1002144-g007" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pcbi.1002144.g007</object-id>
          <label>Figure 7</label>
          <caption>
            <title>Simulation of cell surface presentation of HIV virus peptides by HLA–B2705.</title>
            <p>The sequence of the HIV-1 polyprotein Gag-Pol was obtained from the UniProt online resource (accession P03367). All peptides between 8 and 10 amino acids in length were then derived from the sequence and assessed for their off-rates using the BIMAS prediction algorithm (<ext-link ext-link-type="uri" xlink:href="http://www-bimas.cit.nih.gov/molbio/hla_bind" xlink:type="simple">http://www-bimas.cit.nih.gov/molbio/hla_bind</ext-link> <xref ref-type="bibr" rid="pcbi.1002144-Parker1">[28]</xref>). The peptides were then simulated by assuming that they are all supplied into the ER via TAP at an equal rate, such that the total supply rate is equal to the total supply rate estimated for <xref ref-type="fig" rid="pcbi-1002144-g004">Fig. 4</xref>. As the algorithm predicted many peptides to have the same off-rate, peptides were clustered for ease of computation. (<bold>A</bold>) The number of peptides with a given peptide off-rate, as calculated by BIMAS. (<bold>B</bold>) Steady-state cell surface presentation of peptide-MHC complexes as a function of peptide off-rate. Peptide supply was assumed to be constant for each individual peptide. Therefore, the supply rate associated with a particular off-rate is simply scaled by the number of peptides with that off-rate, as quantified in A. The lowest off-rate (highest affinity) peptides for B2705 (KRWIILGLNK) and B4403 (AETQCETAY) are indicated. Simulations were performed for the presence and absence of tapasin, as indicated in the key. (<bold>C</bold>) Enhancement of cell surface presentation by tapasin was computed by dividing simulated tapasin-sufficient presentation by simulated tapasin-deficient presentation for each peptide. The results of the HIV simulations illustrate the extent to which tapasin can affect a downstream immune response. Theoretically, tapasin can enhance presentation by up to a factor <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e156" xlink:type="simple"/></inline-formula>, where <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e157" xlink:type="simple"/></inline-formula> is the off-rate of the peptide from MHC (<xref ref-type="fig" rid="pcbi-1002144-g005">Fig. 5</xref>). However, the characteristics of the MHC allele, such as the allele-specific peptide on-rate, can significantly alter the effect of tapasin on the presentation of a given peptide. Our model allows differences in presentation levels to be quantified by taking into account peptide supply and peptide off-rate, together with the effects of tapasin and the binding properties of the MHC class I allele under consideration. In particular, our analysis of the HIV-1 Gag-Pol polyprotein provides a specific quantitative prediction for the cell surface presentation of the immunodominant KRWIILGLNK by HLA–B2705. By simulating the range of peptides derived from Gag-Pol, representing a range of off-rates, we observe that the enhancement by tapasin is independent of peptide supply, instead being wholly determined by the peptide off- and on-rates (<xref ref-type="fig" rid="pcbi-1002144-g007">Fig. 7 C</xref>).</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002144.g007" xlink:type="simple"/>
        </fig>
      </sec>
    </sec>
    <sec id="s4">
      <title>Discussion</title>
      <p>The optimization of peptide-MHC class I complexes at the surface of antigen presenting cells is one of the key factors that determines the hierarchy of the T-cell response to a complex antigen <xref ref-type="bibr" rid="pcbi.1002144-Yewdell1">[1]</xref>. Peptide optimization is also important for vaccine design, where vaccine peptides compete with endogenous peptides for presentation <xref ref-type="bibr" rid="pcbi.1002144-Yewdell1">[1]</xref>, <xref ref-type="bibr" rid="pcbi.1002144-Boisgrault1">[30]</xref>. In this paper we propose a dynamical systems model of MHC class I peptide optimization, which takes into account the supply of peptides in the cytosol, the affinity of peptides to MHC and the interactions between peptide and MHC at the different stages of the optimization process, both within the ER and at the cell surface. The model also incorporates the effects of tapasin, which is known to increase peptide optimization <xref ref-type="bibr" rid="pcbi.1002144-Howarth1">[5]</xref> and to affect different MHC class I alleles to different extents <xref ref-type="bibr" rid="pcbi.1002144-Williams1">[6]</xref>. This variation in tapasin dependence may protect from viral immune evasion strategies such as tapasin inhibition by an adenovirus <xref ref-type="bibr" rid="pcbi.1002144-Bennett1">[31]</xref>.</p>
      <p>The dynamical systems model is firmly grounded in experimental data, and techniques already exist to measure many of the model parameters <xref ref-type="bibr" rid="pcbi.1002144-Howarth1">[5]</xref>–<xref ref-type="bibr" rid="pcbi.1002144-Chen1">[8]</xref>. The model therefore allows a multitude of experimental results to be unified within a common framework, so that a range of mechanistic hypotheses can be formulated and tested. We derive a peptide filtering relation which, for the first time, provides a mechanistic explanation for experimental data on MHC class I peptide optimization, both over time <xref ref-type="bibr" rid="pcbi.1002144-Williams1">[6]</xref> and at steady state <xref ref-type="bibr" rid="pcbi.1002144-Howarth1">[5]</xref>. Specifically, it suggests that tapasin enhances peptide off-rate in order to improve peptide optimization without significantly delaying the transit of MHC to the cell surface.</p>
      <p>We have also shown that an allele-specific peptide on-rate is the most likely mechanistic explanation for differences in peptide optimization across HLA–B alleles. A possible interpretation is that differences in peptide on-rate are due to allelic differences in molecular conformation. For example, alleles such as B4402 could adopt a closed conformation, reducing the ability of peptides to bind MHC, while alleles such as B2705 could adopt a more open conformation, allowing peptides to readily bind MHC, as suggested in <xref ref-type="bibr" rid="pcbi.1002144-Peh1">[32]</xref>. When tapasin binds to MHC the peptide binding groove may then adopt a peptide receptive conformation, allowing MHC to bind peptides more readily, as suggested in <xref ref-type="bibr" rid="pcbi.1002144-Sieker1">[20]</xref>. Although allelic differences in the conformation of MHC class I are largely peptide-independent, variations in the on-rates of different peptides have nevertheless been observed. These variations can be incorporated in future versions of the model by allowing a separate on-rate for each peptide. However, published estimates indicate that variations in the affinity of peptide-MHC interactions are mostly governed by variations in peptide off-rate <xref ref-type="bibr" rid="pcbi.1002144-Gakamsky1">[11]</xref>, supporting our assumption that the on-rate is allele-specific and largely peptide-independent.</p>
      <p>Although the current model makes a number of simplifying assumptions on the antigen presentation process, the model can be readily extended to incorporate additional details as more data are acquired. These details could include the explicit contribution of TAP transport, proteasomal cleavage and cytosolic protein abundance to ER peptide supply <xref ref-type="bibr" rid="pcbi.1002144-Peters1">[26]</xref>, <xref ref-type="bibr" rid="pcbi.1002144-Mishto1">[33]</xref>, <xref ref-type="bibr" rid="pcbi.1002144-Tenzer2">[34]</xref>. At present these mechanisms are only implicitly represented in the model via peptide-specific supply rates <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e158" xlink:type="simple"/></inline-formula>. Further extensions could also include conformational changes in MHC <xref ref-type="bibr" rid="pcbi.1002144-Praveen1">[7]</xref>, and chaperones such as ERp57 and calreticulin which are known to influence total cell-surface presentation <xref ref-type="bibr" rid="pcbi.1002144-Wearsch1">[15]</xref>, <xref ref-type="bibr" rid="pcbi.1002144-Howe1">[17]</xref>. Since the mechanisms by which additional chaperones interact with MHC class I are only partially known, we can investigate a variety of hypotheses by using our Information Theoretic framework to assess allele-specific chaperone-dependency. In the future, coupling model analysis with additional experimental measurements will enable quantitative predictions of peptide optimization for a wide range of MHC class I genotypes. Having a robust model, known to make accurate predictions, will improve our ability to assess the efficacy of vaccines involving multiple peptides, and will provide a quantitative means to prioritize different vaccination strategies.</p>
      <p>The current work is part of a broader research programme to use experimental data to build credible mathematical models of immunological processes, ranging from relatively simple examples to complex systems such as organ-specific autoimmunity. The resulting models can then be used to make specific and testable predictions that relate directly to immunological function. Subsequent iterations offer an opportunity to refine or develop the models from the simple to the complex, or from the static to the time-resolved, at the molecular, cellular or organ level.</p>
    </sec>
    <sec id="s5" sec-type="methods">
      <title>Methods</title>
      <sec id="s5a">
        <title>Ordinary differential equation representation of the dynamical systems model</title>
        <p>The chemical reaction representation of the dynamical systems model of <xref ref-type="fig" rid="pcbi-1002144-g002">Fig. 2</xref> is as follows:</p>
        <p>
          <disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e159" xlink:type="simple"/></disp-formula>
        </p>
        <p>By assuming mass-action kinetics, we converted the system of reactions to a set of ordinary differential equations (ODEs), where <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e160" xlink:type="simple"/></inline-formula> denotes the concentration of a given species <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e161" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e162" xlink:type="simple"/></inline-formula> denotes rate of change in concentration.<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e163" xlink:type="simple"/><label>(3)</label></disp-formula><disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e164" xlink:type="simple"/><label>(4)</label></disp-formula><disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e165" xlink:type="simple"/><label>(5)</label></disp-formula><disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e166" xlink:type="simple"/><label>(6)</label></disp-formula><disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e167" xlink:type="simple"/><label>(7)</label></disp-formula><disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e168" xlink:type="simple"/><label>(8)</label></disp-formula><disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e169" xlink:type="simple"/><label>(9)</label></disp-formula><disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e170" xlink:type="simple"/><label>(10)</label></disp-formula></p>
        <p>The dependent variables consist of MHC <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e171" xlink:type="simple"/></inline-formula>, peptide <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e172" xlink:type="simple"/></inline-formula>, tapasin <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e173" xlink:type="simple"/></inline-formula>, egressed MHC <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e174" xlink:type="simple"/></inline-formula> and the complexes formed between these elements. The equations denote a two-compartment system, comprising an ER model (3)–(8) and a cell surface model (9)–(10).</p>
      </sec>
      <sec id="s5b">
        <title>Steady-state analysis of the ODE representation</title>
        <p>Equation (1) was derived by considering the steady state (equilibrium) solutions of the ODE representation. By equating <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e175" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e176" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e177" xlink:type="simple"/></inline-formula> with zero, we obtained the following expressions for <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e178" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e179" xlink:type="simple"/></inline-formula>:<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e180" xlink:type="simple"/><label>(11)</label></disp-formula><disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e181" xlink:type="simple"/><label>(12)</label></disp-formula></p>
        <p>By substituting (12) in (11) we obtained the expression for the steady-state concentration of egressed MHC complexes with a given peptide <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e182" xlink:type="simple"/></inline-formula> in equation (1)<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e183" xlink:type="simple"/></disp-formula></p>
        <p>where <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e184" xlink:type="simple"/></inline-formula>. The equation incorporates the peptide filtering steps described in the main text, where <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e185" xlink:type="simple"/></inline-formula> denotes the optimization of free MHC in the ER, while <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e186" xlink:type="simple"/></inline-formula> denotes the optimization of MHC bound to tapasin in the ER. For a given peptide with off-rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e187" xlink:type="simple"/></inline-formula>, the optimization of free and tapasin-bound MHC is therefore fully determined by <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e188" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e189" xlink:type="simple"/></inline-formula>, respectively. Moreover, MHC complexes optimized in the presence of tapasin will always be subject to an additional optimization step after tapasin unbinding. The equation also incorporates optimization of MHC at the cell surface given by <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e190" xlink:type="simple"/></inline-formula>, where peptides with a lower off-rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e191" xlink:type="simple"/></inline-formula> are more likely to remain bound to MHC.</p>
      </sec>
      <sec id="s5c">
        <title>Optimizing model parameters with respect to experimental data</title>
        <p>Heuristic search methods were used to fine-tune model parameters, based on the available experimental data. Our approach was to minimize a cost function, defined as the sum of the squared differences between experimental data <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e192" xlink:type="simple"/></inline-formula> (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e193" xlink:type="simple"/></inline-formula>) and corresponding model simulated output <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e194" xlink:type="simple"/></inline-formula>, subject to an arbitrary proportionality constant <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e195" xlink:type="simple"/></inline-formula>. i.e.<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e196" xlink:type="simple"/><label>(13)</label></disp-formula><disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e197" xlink:type="simple"/><label>(14)</label></disp-formula></p>
        <p>where <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e198" xlink:type="simple"/></inline-formula> is the space of search parameters, which may be the full parameter set or a subset thereof. For the inner minimization problem (14), it is possible to assign an optimal <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e199" xlink:type="simple"/></inline-formula>, by equating the partial derivative of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e200" xlink:type="simple"/></inline-formula> (with respect to <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e201" xlink:type="simple"/></inline-formula>) to 0.<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e202" xlink:type="simple"/><label>(15)</label></disp-formula><disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e203" xlink:type="simple"/><label>(16)</label></disp-formula></p>
        <p>Approximate minimizers of the multi-dimensional objective function (13) were found using a Metropolis-Hastings (MH) algorithm.</p>
        <p>During execution of the MH algorithm, a Markov chain of proposal parameter sets is formed. Starting from an initial parameter set <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e204" xlink:type="simple"/></inline-formula> with associated objective function value <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e205" xlink:type="simple"/></inline-formula>, the algorithm iteratively searches neighboring parameter sets by accepting or rejecting new proposal parameter sets at each step. Neighboring points <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e206" xlink:type="simple"/></inline-formula> are proposed with probability <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e207" xlink:type="simple"/></inline-formula>, according to a <italic>jump rule</italic><disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e208" xlink:type="simple"/><label>(17)</label></disp-formula></p>
        <p>The chain moves to the new point <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e209" xlink:type="simple"/></inline-formula> according to an acceptance criterion, which makes a probabilistic choice about whether to accept <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e210" xlink:type="simple"/></inline-formula>. Given an observation <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e211" xlink:type="simple"/></inline-formula> drawn from <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e212" xlink:type="simple"/></inline-formula>, the proposal point is accepted providing<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e213" xlink:type="simple"/></disp-formula></p>
        <p>where <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e214" xlink:type="simple"/></inline-formula> is the probability that the parameter set <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e215" xlink:type="simple"/></inline-formula> matches the data and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e216" xlink:type="simple"/></inline-formula> is the proposal density (which we fix to be symmetric). Assuming the deviations from the experimental data are Gaussian distributed and that <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e217" xlink:type="simple"/></inline-formula> makes only small jumps, the acceptance ratio is approximately given by<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e218" xlink:type="simple"/></disp-formula></p>
        <p>Note that when <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e219" xlink:type="simple"/></inline-formula> we always move to <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e220" xlink:type="simple"/></inline-formula>, because the exponential function of a positive number is greater than one. The algorithm iterates until some termination condition is reached, such as a maximum number of iterations or a convergence condition. All parameter searches were performed using ‘Filzbach’, a software library for carrying out Metropolis-Hastings Markov chain Monte Carlo parameter estimation in C++ or C#. Filzbach is under development in the computational science lab at Microsoft Research Cambridge and is available for download, complete with a suite of example uses, via <ext-link ext-link-type="uri" xlink:href="http://research.microsoft.com/science" xlink:type="simple">http://research.microsoft.com/science</ext-link>.</p>
      </sec>
      <sec id="s5d">
        <title>Model selection using the Bayesian Information Criterion</title>
        <p>To assess which model parameter(s) should be allele-specific, different hypotheses were compared using the Bayesian Information Criterion (BIC) <xref ref-type="bibr" rid="pcbi.1002144-Konishi1">[19]</xref>. The BIC is defined as<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e221" xlink:type="simple"/><label>(18)</label></disp-formula></p>
        <p>where <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e222" xlink:type="simple"/></inline-formula> is the parameter set associated with model hypothesis <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e223" xlink:type="simple"/></inline-formula> that maximizes the likelihood function <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e224" xlink:type="simple"/></inline-formula>, and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e225" xlink:type="simple"/></inline-formula> are the experimental observations. This is equivalent to minimizing the residual sum of squares, as in (14). It can be seen from this equation that the BIC penalizes the introduction of additional parameters.</p>
      </sec>
      <sec id="s5e">
        <title>Solving the model equations</title>
        <p>The model equations (3)–(10) were solved throughout using the CVODE routine <xref ref-type="bibr" rid="pcbi.1002144-Cohen1">[35]</xref>, as part of SUNDIALS suite of numerical integrators <xref ref-type="bibr" rid="pcbi.1002144-Hindmarsh1">[36]</xref>. During optimization with Filzbach, simulation code was written in C and compiled using Microsoft Visual Studio 2010. For plotting the simulations results, we used MATLAB and the SUNDIALS Toolbox for MATLAB. We have also provided an implementation of the model in SBML format for HLA–B (<xref ref-type="supplementary-material" rid="pcbi.1002144.s001">Protocol S1</xref>) and H2−<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e226" xlink:type="simple"/></inline-formula> (<xref ref-type="supplementary-material" rid="pcbi.1002144.s002">Protocol S2</xref>).</p>
      </sec>
      <sec id="s5f">
        <title>Computing the equilibrium concentrations</title>
        <p>The equilibrium concentrations were computed from the model equations by equating the right hand sides to zero. This amounts to solving a system of nonlinear equations <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e227" xlink:type="simple"/></inline-formula>, where <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e228" xlink:type="simple"/></inline-formula> is the vector of concentrations and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e229" xlink:type="simple"/></inline-formula> describes the fluxes resulting from production, degradation, binding, unbinding and ER egression. When using MATLAB, we used an implementation of the Levenberg-Marquhardt (L–M) search algorithm <xref ref-type="bibr" rid="pcbi.1002144-Fletcher1">[37]</xref> to find solutions. When using the C implementation or in the case where the L–M algorithm did not converge to a non-negative solution, the ODEs were simulated using CVODE until the solution had not changed by more than 0.1% over a time interval of 1000 minutes. The latter method guarantees a non-negative solution providing the initial condition is also non-negative.</p>
      </sec>
      <sec id="s5g">
        <title>Decay of MHC class I from the cell-surface with Brefeldin A</title>
        <p>Brefeldin A (BFA) blocks anterograde traffic from the ER and thus the Golgi fuses with the ER. This prevents export of any newly synthesized class I from the ER to the cell-surface <xref ref-type="bibr" rid="pcbi.1002144-Yewdell3">[38]</xref>, <xref ref-type="bibr" rid="pcbi.1002144-Nuchtern1">[39]</xref>. BFA (Sigma, UK) was dissolved in methanol at 4 mg/ml for storage at <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e230" xlink:type="simple"/></inline-formula> and used at 5 <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e231" xlink:type="simple"/></inline-formula>. <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e232" xlink:type="simple"/></inline-formula> suspension cells were plated in 1 ml cell medium in a 24-well plate. 5 <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e233" xlink:type="simple"/></inline-formula> BFA was added for the indicated times and all the cells were harvested at the same time for flow cytometry. Cells were harvested for flow cytometry as previously described <xref ref-type="bibr" rid="pcbi.1002144-Howarth1">[5]</xref>.</p>
      </sec>
    </sec>
    <sec id="s6">
      <title>Supporting Information</title>
      <supplementary-material id="pcbi.1002144.s001" mimetype="text/xml" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002144.s001" xlink:type="simple">
        <label>Protocol S1</label>
        <caption>
          <p>An implementation of the model in SBML format for HLA-B.</p>
          <p>(XML)</p>
        </caption>
      </supplementary-material>
      <supplementary-material id="pcbi.1002144.s002" mimetype="text/xml" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002144.s002" xlink:type="simple">
        <label>Protocol S2</label>
        <caption>
          <p>An implementation of the model in SBML format for H2-<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002144.e234" xlink:type="simple"/></inline-formula>.</p>
          <p>(XML)</p>
        </caption>
      </supplementary-material>
      <supplementary-material id="pcbi.1002144.s003" mimetype="application/pdf" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002144.s003" xlink:type="simple">
        <label>Text S1</label>
        <caption>
          <p>Supporting information<bold>.</bold> Here we outline in more detail the derivation of the model and the filter relation, and provide interpretation for parameter variation analyses. Included are 8 supplementary figures and 3 supplementary tables.</p>
          <p>(PDF)</p>
        </caption>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="pcbi.1002144-Yewdell1">
        <label>1</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Yewdell</surname><given-names>JW</given-names></name><name name-style="western"><surname>Bennink</surname><given-names>JR</given-names></name></person-group>             <year>1999</year>             <article-title>Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses.</article-title>             <source>Ann Rev of Immunol</source>             <volume>17</volume>             <fpage>51</fpage>             <lpage>88</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002144-Yewdell2">
        <label>2</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Yewdell</surname><given-names>JW</given-names></name><name name-style="western"><surname>Reits</surname><given-names>E</given-names></name><name name-style="western"><surname>Neefjes</surname><given-names>J</given-names></name></person-group>             <year>2003</year>             <article-title>Making sense of mass destruction: quantitating MHC class I antigen presentation.</article-title>             <source>Nat Rev Immunol</source>             <volume>3</volume>             <fpage>952</fpage>             <lpage>961</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002144-Elliott1">
        <label>3</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Elliott</surname><given-names>T</given-names></name><name name-style="western"><surname>Williams</surname><given-names>A</given-names></name></person-group>             <year>2005</year>             <article-title>The optimization of peptide cargo bound to MHC class I molecules by the peptide-loading complex.</article-title>             <source>Immunol Rev</source>             <volume>207</volume>             <fpage>89</fpage>             <lpage>99</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002144-Wright1">
        <label>4</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Wright</surname><given-names>CA</given-names></name><name name-style="western"><surname>Kozik</surname><given-names>P</given-names></name><name name-style="western"><surname>Zacharias</surname><given-names>M</given-names></name><name name-style="western"><surname>Springer</surname><given-names>S</given-names></name></person-group>             <year>2004</year>             <article-title>Tapasin and other chaperones: models of the MHC class I loading complex.</article-title>             <source>Biol Chem</source>             <volume>385</volume>             <fpage>763</fpage>             <lpage>778</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002144-Howarth1">
        <label>5</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Howarth</surname><given-names>M</given-names></name><name name-style="western"><surname>Williams</surname><given-names>A</given-names></name><name name-style="western"><surname>Tolstrup</surname><given-names>AB</given-names></name><name name-style="western"><surname>Elliott</surname><given-names>T</given-names></name></person-group>             <year>2004</year>             <article-title>Tapasin enhances MHC class I peptide presentation according to peptide half-life.</article-title>             <source>Proc Natl Acad Sci U S A</source>             <volume>101</volume>             <fpage>11737</fpage>             <lpage>11742</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002144-Williams1">
        <label>6</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Williams</surname><given-names>AP</given-names></name><name name-style="western"><surname>Peh</surname><given-names>CA</given-names></name><name name-style="western"><surname>Purcell</surname><given-names>AW</given-names></name><name name-style="western"><surname>McCluskey</surname><given-names>J</given-names></name><name name-style="western"><surname>Elliott</surname><given-names>T</given-names></name></person-group>             <year>2002</year>             <article-title>Optimization of the MHC class I peptide cargo is dependent on tapasin.</article-title>             <source>Immunity</source>             <volume>16</volume>             <fpage>509</fpage>             <lpage>520</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002144-Praveen1">
        <label>7</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Praveen</surname><given-names>PVK</given-names></name><name name-style="western"><surname>Yaneva</surname><given-names>R</given-names></name><name name-style="western"><surname>Kalbacher</surname><given-names>H</given-names></name><name name-style="western"><surname>Springer</surname><given-names>S</given-names></name></person-group>             <year>2009</year>             <article-title>Tapasin edits peptides on MHC class I molecules by accelerating peptide exchange.</article-title>             <source>Eur J Immunol</source>             <volume>40</volume>             <fpage>214</fpage>             <lpage>224</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002144-Chen1">
        <label>8</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>M</given-names></name><name name-style="western"><surname>Bouvier</surname><given-names>M</given-names></name></person-group>             <year>2007</year>             <article-title>Analysis of interactions in a tapasin/class I complex provides a mechanism for peptide selection.</article-title>             <source>EMBO J</source>             <volume>26</volume>             <fpage>1681</fpage>             <lpage>1690</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002144-Schneeweiss1">
        <label>9</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Schneeweiss</surname><given-names>C</given-names></name><name name-style="western"><surname>Garstka</surname><given-names>M</given-names></name><name name-style="western"><surname>Smith</surname><given-names>J</given-names></name><name name-style="western"><surname>Htt</surname><given-names>MT</given-names></name><name name-style="western"><surname>Springer</surname><given-names>S</given-names></name></person-group>             <year>2009</year>             <article-title>The mechanism of action of tapasin in the peptide exchange on MHC class I molecules determined from kinetics simulation studies.</article-title>             <source>Mol Immunol</source>             <volume>46</volume>             <fpage>2054</fpage>             <lpage>2063</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002144-Phillips1">
        <label>10</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Phillips</surname><given-names>A</given-names></name><name name-style="western"><surname>Cardelli</surname><given-names>L</given-names></name></person-group>             <year>2007</year>             <article-title>Efficient, correct simulation of biological processes in the stochastic pi-calculus. In: Computational Methods in Systems Biology.</article-title>             <source>Springer, volume 4695 of LNCS,</source>             <volume>184–199</volume>          </element-citation>
      </ref>
      <ref id="pcbi.1002144-Gakamsky1">
        <label>11</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Gakamsky</surname><given-names>DM</given-names></name><name name-style="western"><surname>Davis</surname><given-names>DM</given-names></name><name name-style="western"><surname>Strominger</surname><given-names>JL</given-names></name><name name-style="western"><surname>Pecht</surname><given-names>I</given-names></name></person-group>             <year>2000</year>             <article-title>Assembly and dissociation of human leukocyte antigen (HLA)-A2 studied by real-time uorescence resonance energy transfer.</article-title>             <source>Biochemistry</source>             <volume>39</volume>             <fpage>11163</fpage>             <lpage>11169</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002144-Paulsson1">
        <label>12</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Paulsson</surname><given-names>KM</given-names></name><name name-style="western"><surname>Kleijmeer</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Griffith</surname><given-names>J</given-names></name><name name-style="western"><surname>Jevon</surname><given-names>M</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S</given-names></name><etal/></person-group>             <year>2002</year>             <article-title>Association of tapasin and COPI provides a mechanism for the retrograde transport of major histocompatibility complex (MHC) class I molecules from the Golgi complex to the endoplasmic reticulum.</article-title>             <source>J Biol Chem</source>             <volume>277</volume>             <fpage>18266</fpage>             <lpage>18271</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002144-Garstka1">
        <label>13</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Garstka</surname><given-names>M</given-names></name><name name-style="western"><surname>Borchert</surname><given-names>B</given-names></name><name name-style="western"><surname>Al-Balushi</surname><given-names>M</given-names></name><name name-style="western"><surname>Praveen</surname><given-names>PVK</given-names></name><name name-style="western"><surname>Khl</surname><given-names>N</given-names></name><etal/></person-group>             <year>2007</year>             <article-title>Peptide-receptive major histocompatibility complex class I molecules cycle between endoplasmic reticulum and cis-Golgi in wild-type lymphocytes.</article-title>             <source>J Biol Chem</source>             <volume>282</volume>             <fpage>30680</fpage>             <lpage>30690</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002144-Lehner1">
        <label>14</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Lehner</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Surman</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Cresswell</surname><given-names>P</given-names></name></person-group>             <year>1998</year>             <article-title>Soluble tapasin restores MHC class I expression and function in the tapasin-negative cell line .220.</article-title>             <source>Immunity</source>             <volume>8</volume>             <fpage>221</fpage>             <lpage>231</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002144-Wearsch1">
        <label>15</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Wearsch</surname><given-names>PA</given-names></name><name name-style="western"><surname>Cresswell</surname><given-names>P</given-names></name></person-group>             <year>2007</year>             <article-title>Selective loading of high-affinity peptides onto major histocom-patibility complex class I molecules by the tapasin-ERp57 heterodimer.</article-title>             <source>Nat Immunol</source>             <volume>8</volume>             <fpage>873</fpage>             <lpage>881</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002144-Gao1">
        <label>16</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>B</given-names></name><name name-style="western"><surname>Adhikari</surname><given-names>R</given-names></name><name name-style="western"><surname>Howarth</surname><given-names>M</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>K</given-names></name><name name-style="western"><surname>Gold</surname><given-names>MC</given-names></name><etal/></person-group>             <year>2002</year>             <article-title>Assembly and antigen- presenting function of MHC class I molecules in cells lacking the ER chaperone calreticulin.</article-title>             <source>Immunity</source>             <volume>16</volume>             <fpage>99</fpage>             <lpage>109</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002144-Howe1">
        <label>17</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Howe</surname><given-names>C</given-names></name><name name-style="western"><surname>Garstka</surname><given-names>M</given-names></name><name name-style="western"><surname>Al-Balushi</surname><given-names>M</given-names></name><name name-style="western"><surname>Ghanem</surname><given-names>E</given-names></name><name name-style="western"><surname>Antoniou</surname><given-names>AN</given-names></name><etal/></person-group>             <year>2009</year>             <article-title>Calreticulin-dependent recycling in the early secretory pathway mediates optimal peptide loading of MHC class I molecules.</article-title>             <source>EMBO J</source>             <volume>28</volume>             <fpage>3730</fpage>             <lpage>3744</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002144-Goulder1">
        <label>18</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Goulder</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>RE</given-names></name><name name-style="western"><surname>Colbert</surname><given-names>RA</given-names></name><name name-style="western"><surname>McAdam</surname><given-names>S</given-names></name><name name-style="western"><surname>Ogg</surname><given-names>G</given-names></name><etal/></person-group>             <year>1997</year>             <article-title>Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS.</article-title>             <source>Nat Med</source>             <volume>3</volume>             <fpage>212</fpage>             <lpage>217</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002144-Konishi1">
        <label>19</label>
        <element-citation publication-type="other" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Konishi</surname><given-names>S</given-names></name><name name-style="western"><surname>Kitagawa</surname><given-names>G</given-names></name></person-group>             <year>2008</year>             <article-title>Information Criteria and Statistical Modeling.</article-title>             <publisher-name>Springer</publisher-name>          </element-citation>
      </ref>
      <ref id="pcbi.1002144-Sieker1">
        <label>20</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Sieker</surname><given-names>F</given-names></name><name name-style="western"><surname>Straatsma</surname><given-names>TP</given-names></name><name name-style="western"><surname>Springer</surname><given-names>S</given-names></name><name name-style="western"><surname>Zacharias</surname><given-names>M</given-names></name></person-group>             <year>2008</year>             <article-title>Differential tapasin dependence of MHC class I molecules correlates with conformational changes upon peptide dissociation: a molecular dynamics simulation study.</article-title>             <source>Mol Immunol</source>             <volume>45</volume>             <fpage>3714</fpage>             <lpage>3722</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002144-vanderBurg1">
        <label>21</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>van der Burg</surname><given-names>SH</given-names></name><name name-style="western"><surname>Visseren</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Brandt</surname><given-names>RM</given-names></name><name name-style="western"><surname>Kast</surname><given-names>WM</given-names></name><name name-style="western"><surname>Melief</surname><given-names>CJ</given-names></name></person-group>             <year>1996</year>             <article-title>Immunogenicity of peptides bound to mhc class i molecules depends on the mhc-peptide complex stability.</article-title>             <source>J Immunol</source>             <volume>156</volume>             <fpage>3308</fpage>             <lpage>3314</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002144-Lewis1">
        <label>22</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Lewis</surname><given-names>JW</given-names></name><name name-style="western"><surname>Elliott</surname><given-names>T</given-names></name></person-group>             <year>1998</year>             <article-title>Evidence for successive peptide binding and quality control stages during MHC class I assembly.</article-title>             <source>Curr Biol</source>             <volume>8</volume>             <fpage>717</fpage>             <lpage>720</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002144-Hopfield1">
        <label>23</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Hopfield</surname><given-names>JJ</given-names></name></person-group>             <year>1974</year>             <article-title>Kinetic proofreading: a new mechanism for reducing errors in biosynthetic processes requiring high specificity.</article-title>             <source>Proc Natl Acad Sci U S A</source>             <volume>71</volume>             <fpage>4135</fpage>             <lpage>4139</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002144-Blanchard1">
        <label>24</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Blanchard</surname><given-names>N</given-names></name><name name-style="western"><surname>Shastri</surname><given-names>N</given-names></name></person-group>             <year>2008</year>             <article-title>Coping with loss of perfection in the MHC class I peptide repertoire.</article-title>             <source>Curr Opin Immunol</source>             <volume>20</volume>             <fpage>82</fpage>             <lpage>88</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002144-Porgador1">
        <label>25</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Porgador</surname><given-names>A</given-names></name><name name-style="western"><surname>Yewdell</surname><given-names>JW</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Bennink</surname><given-names>JR</given-names></name><name name-style="western"><surname>Germain</surname><given-names>RN</given-names></name></person-group>             <year>1997</year>             <article-title>Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody.</article-title>             <source>Immunity</source>             <volume>6</volume>             <fpage>715</fpage>             <lpage>726</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002144-Peters1">
        <label>26</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Peters</surname><given-names>B</given-names></name><name name-style="western"><surname>Bulik</surname><given-names>S</given-names></name><name name-style="western"><surname>Tampe</surname><given-names>R</given-names></name><name name-style="western"><surname>Endert</surname><given-names>PMV</given-names></name><name name-style="western"><surname>Holzhtter</surname><given-names>HG</given-names></name></person-group>             <year>2003</year>             <article-title>Identifying MHC class I epitopes by predicting the TAP transport efficiency of epitope precursors.</article-title>             <source>J Immunol</source>             <volume>171</volume>             <fpage>1741</fpage>             <lpage>1749</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002144-Tenzer1">
        <label>27</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Tenzer</surname><given-names>S</given-names></name><name name-style="western"><surname>Wee</surname><given-names>E</given-names></name><name name-style="western"><surname>Burgevin</surname><given-names>A</given-names></name><name name-style="western"><surname>Stewart-Jones</surname><given-names>G</given-names></name><name name-style="western"><surname>Friis</surname><given-names>L</given-names></name><etal/></person-group>             <year>2009</year>             <article-title>Antigen processing inuences HIV-specific cytotoxic T lymphocyte immunodominance.</article-title>             <source>Nat Immunol</source>             <volume>10</volume>             <fpage>636</fpage>             <lpage>646</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002144-Parker1">
        <label>28</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Parker</surname><given-names>KC</given-names></name><name name-style="western"><surname>Bednarek</surname><given-names>MA</given-names></name><name name-style="western"><surname>Coligan</surname><given-names>JE</given-names></name></person-group>             <year>1994</year>             <article-title>Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains.</article-title>             <source>J Immunol</source>             <volume>152</volume>             <fpage>163</fpage>             <lpage>175</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002144-Nixon1">
        <label>29</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Nixon</surname><given-names>DF</given-names></name><name name-style="western"><surname>Townsend</surname><given-names>AR</given-names></name><name name-style="western"><surname>Elvin</surname><given-names>JG</given-names></name><name name-style="western"><surname>Rizza</surname><given-names>CR</given-names></name><name name-style="western"><surname>Gallwey</surname><given-names>J</given-names></name><etal/></person-group>             <year>1988</year>             <article-title>HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides.</article-title>             <source>Nature</source>             <volume>336</volume>             <fpage>484</fpage>             <lpage>487</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002144-Boisgrault1">
        <label>30</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Boisgérault</surname><given-names>F</given-names></name><name name-style="western"><surname>Tieng</surname><given-names>V</given-names></name><name name-style="western"><surname>Stolzenberg</surname><given-names>MC</given-names></name><name name-style="western"><surname>Dulphy</surname><given-names>N</given-names></name><name name-style="western"><surname>Khalil</surname><given-names>I</given-names></name><etal/></person-group>             <year>1996</year>             <article-title>Differences in endogenous peptides presented by HLA-B*2705 and B*2703 allelic variants. implications for susceptibility to spondylarthropathies.</article-title>             <source>J Clin Invest</source>             <volume>98</volume>             <fpage>2764</fpage>             <lpage>2770</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002144-Bennett1">
        <label>31</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Bennett</surname><given-names>EM</given-names></name><name name-style="western"><surname>Bennink</surname><given-names>JR</given-names></name><name name-style="western"><surname>Yewdell</surname><given-names>JW</given-names></name><name name-style="western"><surname>Brodsky</surname><given-names>FM</given-names></name></person-group>             <year>1999</year>             <article-title>Cutting edge: adenovirus E19 has two mechanisms for affecting class I MHC expression.</article-title>             <source>J Immunol</source>             <volume>162</volume>             <fpage>5049</fpage>             <lpage>5052</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002144-Peh1">
        <label>32</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Peh</surname><given-names>CA</given-names></name><name name-style="western"><surname>Burrows</surname><given-names>SR</given-names></name><name name-style="western"><surname>Barnden</surname><given-names>M</given-names></name><name name-style="western"><surname>Khanna</surname><given-names>R</given-names></name><name name-style="western"><surname>Cresswell</surname><given-names>P</given-names></name><etal/></person-group>             <year>1998</year>             <article-title>Hla-b27-restricted antigen presentation in the absence of tapasin reveals polymorphism in mechanisms of hla class i peptide loading.</article-title>             <source>Immunity</source>             <volume>8</volume>             <fpage>531</fpage>             <lpage>542</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002144-Mishto1">
        <label>33</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Mishto</surname><given-names>M</given-names></name><name name-style="western"><surname>Luciani</surname><given-names>F</given-names></name><name name-style="western"><surname>Holzhtter</surname><given-names>HG</given-names></name><name name-style="western"><surname>Bellavista</surname><given-names>E</given-names></name><name name-style="western"><surname>Santoro</surname><given-names>A</given-names></name><etal/></person-group>             <year>2008</year>             <article-title>Modeling the in vitro 20 S proteasome activity: the effect of PA28-αβ and of the sequence and length of polypeptides on the degradation kinetics.</article-title>             <source>J Mol Biol</source>             <volume>377</volume>             <fpage>1607</fpage>             <lpage>1617</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002144-Tenzer2">
        <label>34</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Tenzer</surname><given-names>S</given-names></name><name name-style="western"><surname>Peters</surname><given-names>B</given-names></name><name name-style="western"><surname>Bulik</surname><given-names>S</given-names></name><name name-style="western"><surname>Schoor</surname><given-names>O</given-names></name><name name-style="western"><surname>Lemmel</surname><given-names>C</given-names></name><etal/></person-group>             <year>2005</year>             <article-title>Modeling the MHC class I pathway by combining predictions of proteasomal cleavage, TAP transport and MHC class I binding.</article-title>             <source>Cell Mol Life Sci</source>             <volume>62</volume>             <fpage>1025</fpage>             <lpage>1037</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002144-Cohen1">
        <label>35</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>SD</given-names></name><name name-style="western"><surname>Hindmarsh</surname><given-names>AC</given-names></name></person-group>             <year>1996</year>             <article-title>CVODE, a stiff/nonstiff ODE solver in C. </article-title>             <source>Comput Phys</source>             <volume>10</volume>             <fpage>138</fpage>             <lpage>143</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002144-Hindmarsh1">
        <label>36</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Hindmarsh</surname><given-names>AC</given-names></name><name name-style="western"><surname>Brown</surname><given-names>PN</given-names></name><name name-style="western"><surname>Grant</surname><given-names>KE</given-names></name><name name-style="western"><surname>Lee</surname><given-names>SL</given-names></name><name name-style="western"><surname>Serban</surname><given-names>R</given-names></name><etal/></person-group>             <year>2005</year>             <article-title>SUNDIALS: Suite of nonlinear and differential/algebraic equation solvers.</article-title>             <source>ACM Trans Math Softw</source>             <volume>31</volume>             <fpage>363</fpage>             <lpage>396</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002144-Fletcher1">
        <label>37</label>
        <element-citation publication-type="other" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Fletcher</surname><given-names>R</given-names></name></person-group>             <year>1971</year>             <article-title>A modified Marquardt subroutine for nonlinear least squares.</article-title>             <publisher-name>Technical Report AERE-R 6799, Harwell</publisher-name>          </element-citation>
      </ref>
      <ref id="pcbi.1002144-Yewdell3">
        <label>38</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Yewdell</surname><given-names>JW</given-names></name><name name-style="western"><surname>Bennink</surname><given-names>JR</given-names></name></person-group>             <year>1989</year>             <article-title>Brefeldin A specifically inhibits presentation of protein antigens to cytotoxic T lymphocytes.</article-title>             <source>Science</source>             <volume>244</volume>             <fpage>1072</fpage>             <lpage>1075</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002144-Nuchtern1">
        <label>39</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Nuchtern</surname><given-names>JG</given-names></name><name name-style="western"><surname>Biddison</surname><given-names>WE</given-names></name><name name-style="western"><surname>Klausner</surname><given-names>RD</given-names></name></person-group>             <year>1990</year>             <article-title>Class II MHC molecules can use the endogenous pathway of antigen presentation.</article-title>             <source>Nature</source>             <volume>343</volume>             <fpage>74</fpage>             <lpage>76</lpage>          </element-citation>
      </ref>
    </ref-list>
    
  </back>
</article>